Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.54 |
| ▸ | AGXT | P21549 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | PRKDC | P78527 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitrogen SCHEMBL8429553 | 0.97 | ADRB1 (0.61) | ADRB1MAPTNPC1DRD2KCNH2 | |
| Nitrogen SCHEMBL1855134 | 0.95 | ADRB1 (0.59) | ADRB1MAPTNPC1DRD2KCNH2 | |
| SCHEMBL11074672 | 0.87 | ADRB1 (0.76) | ADRB1MAPTNPC1DRD2KCNH2 | |
| SCHEMBL19212406 | 0.85 | ADRB1 (0.69) | ADRB1MAPTNPC1DRD2KCNH2 | |
| SCHEMBL29194717 | 0.85 | MAPT (0.64) | ADRB1MAPTDRD2KCNH2GAA | |
| SCHEMBL30246093 | 0.85 | MAPT (0.64) | ADRB1MAPTDRD2KCNH2GAA | |
| SCHEMBL23675047 | 0.83 | ADRB1 (0.71) | ADRB1MAPTNPC1DRD2KCNH2 | |
| SCHEMBL5448570 | 0.83 | ADRB1 (0.61) | ADRB1MAPTALOX15HSD17B10L3MBTL1 | |
| SCHEMBL3051915 | 0.83 | ADRB1 (0.71) | ADRB1MAPTNPC1DRD2KCNH2 | |
| SCHEMBL30255158 | 0.83 | ADRB1 (0.71) | ADRB1MAPTNPC1DRD2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113135835-A | Method for exciting C-C bond breaking acylation and application | 广州中医药大学(广州中医药研究院) | 2021-07-20 | — | — | CN | claimed |
| EP-1351946-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2003-10-15 | — | — | EP | claimed |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | LUITPOLD PHARMACEUTICALS, INC. | 2002-11-07 | — | — | US | claimed |
| WO-2002020500-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2002-03-14 | — | — | WO | claimed |
| EP-0673784-B1 | Recording sheets containing oxazole, isooxazole, oxazolidinone, oxazoline salts, morpholine, thiazole, thiazolidine, thiadiazole, and phenothiazine compounds | XEROX CORP (US) | 1999-10-27 | — | — | EP | claimed |
| US-12392042-B2 | Alternating current (AC) transition-metal catalysis | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2025-08-19 | — | — | US | disclosed |
| US-20230407492-A1 | ALTERNATING CURRENT (AC) TRANSITION-METAL CATALYSIS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-12-21 | — | — | US | disclosed |
| EP-4214355-A1 | ALTERNATING CURRENT (AC) TRANSITION-METAL CATALYSIS | Yeda Research and Development Co. Ltd (IL) | 2023-07-26 | — | — | EP | disclosed |
| CN-116113728-A | Alternating Current (AC) transition metal catalysis | 耶达研究与发展有限公司 | 2023-05-12 | — | — | CN | disclosed |
| WO-2022203429-A1 | COMPOSITION FOR PREVENTING OR TREATING MULTIPLE SCLEROSIS | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2022-09-29 | — | — | WO | disclosed |
| CN-111217816-B | FLT3 kinase inhibitor and preparation and application thereof | 中国科学院上海药物研究所 | 2022-08-16 | — | — | CN | disclosed |
| CN-111116653-B | Preparation method of pyrazole-triazole phosphine compound | 河北工业大学 | 2022-08-12 | — | — | CN | disclosed |
| WO-2002020500-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2002-03-14 | — | — | WO | disclosed |
| EP-0802173-B1 | Process for producing heterocylic aromatic amine or arylamine | TOSOH CORP (JP) | 2001-12-19 | — | — | EP | disclosed |
| US-6235938-B1 | ARYLATION IN THE PRESENCE OF A BASE AND TRANSITION METAL CATALYSTS TO FORM N-ARYLAMINE AND GROUP 8 METAL | YALE UNIVERSITY | 2001-05-22 | — | — | US | disclosed |
| EP-1025095-A1 | SUBSTITUTED CHROMAN DERIVATIVES | AstraZeneca AB (SE) | 2000-08-09 | — | — | EP | disclosed |
| US-5929281-A | REACTING A HETROCYCLIC AROMATIC HALIDE WITH AN AMINE COMPOUND IN PRESENCE OF A BASE USING A TRI-TERT-BUTYLPHOSPHINE AND PALLADIUM COMPOUND CATALYST TO FORM HETEROCYCLIC AROMATIC AMINE COMPOUNDS | TOSOH CORPORATION (JP) | 1999-07-27 | — | — | US | disclosed |
| WO-1999014212-A1 | SUBSTITUTED CHROMAN DERIVATIVES | ASTRAZENECA AB (SE) | 1999-03-25 | — | — | WO | disclosed |
| EP-0802173-A1 | Process for producing heterocylic aromatic amine or arylamine | Tosoh Corporation (JP) | 1997-10-22 | — | — | EP | disclosed |
| US-4200751-A | COLOR-FORMING AGENTS | YAMAMOTO KAGAKU GOSEI CO., LTD. (JP) | 1980-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | DCK, CHEK2, CHEK1 | ADRB1 4505/4885MAPT 4502/4885NPC1 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.